Renaissance Capital logo

Akebia Therapeutics Priced, Nasdaq: AKBA

Biotech developing a breakthrough anemia treatment with a once-daily oral dose.

Industry: Health Care

First Day Return: +57.1%

Biotech developing a breakthrough anemia treatment with a once-daily oral dose.
IPO Data
IPO Date 03/19/2014
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $100
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters Cambridge, MA, United States
Founded 2007
Employees at IPO 28
Website www.akebia.com

Akebia Therapeutics (AKBA) Performance

Created with Highcharts 10.3.2Chart context menuAKBA vs. IPO Index (IPOUSA)20152016201720182019202020212022202320242025-100%0%+ 100%+ 200%+ 300%View 5 days5dView 1 month1mView 3 months3mView year to dateYTDView 1 year1yView allAllRenaissance IPO IndexOur ETF tracks the IPO Index